Medicine Recommendations

LSCMMG

Amber 2

BwD

Red

Amber 2

Amber 2

Red

Amber 2

Amber 2

Amber 2

Amber 2

Methotrexate Subcutaneous Injection Pen

Date Posted: 01 - May - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Severe Eczema, Lichen Planus, Felty’s syndrome (unlicensed)

Amber 2

Red

Amber 2

Amber 2

Red

Amber 2

Amber 2

Amber 2

Amber 2

Methotrexate Subcutaneous Injection Pen

Date Posted: 01 - May - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Severe Psoriatic Arthritis

Amber 1

Pending

Amber 1

Amber 1

Pending

Amber 1

Amber 1

Amber 1

Pending

Mycophenolate Mofetil

Date Posted: 01 - Jul - 2017

BNF chapter: Musculoskeletal system Respiratory system

Expand/Collapse

Off label indications as defined in the LSCMMG Shared Care Guidelines

Green

Pending

Green

Pending

Pending

Green

Pending

Pending

Pending

Naproxen

Date Posted: 01 - Jan - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Green

Pending

Green

Pending

Pending

Green

Pending

Pending

Pending

Naproxen

Date Posted: 01 - Jan - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Pain

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Penicillamine

Date Posted: 01 - May - 2013

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatic diseases

Red

Red

Red

Red

Red

Red

Red

Red

Red

Risankizumab

Date Posted: 14 - Sep - 2022

BNF chapter: Musculoskeletal system

Expand/Collapse

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803

NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Red

Red

Red

Red

Red

Red

Red

Red

Red

Rituximab

Date Posted: 01 - May - 2013

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid arthritis (LSCMMG pathway)

Black

Black

Black

Black

Black

Black

Black

Black

Black

Rubefacients (excluding topical non-steroidal anti-inflammatory drugs)

Date Posted: 01 - Dec - 2017

BNF chapter: Musculoskeletal system

Expand/Collapse

This colour classification is in agreement with the recommendations contained within the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017

Red

Red

Red

Red

Red

Red

Red

Red

Red

Sarilumab

Date Posted: 01 - Dec - 2017

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid arthritis (LSCMMG pathway)

Red

Red

Red

Red

Red

Red

Red

Red

Red

Secukinumab

Date Posted: 10 - Sep - 2021

BNF chapter: Musculoskeletal system

Expand/Collapse

For treating non-radiographic axial spondyloarthritis.

NICE TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis

Red

Red

Red

Red

Red

Red

Red

Red

Red

Secukinumab

Date Posted: 01 - Oct - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)

NICE TA407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

Red

Red

Red

Red

Red

Red

Red

Red

Red

Secukinumab

Date Posted: 01 - Jun - 2017

BNF chapter: Musculoskeletal system

Expand/Collapse

Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)

NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Black

Black

Black

Black

Black

Black

Black

Black

Black

Sodium hyaluronate and Triamcinolone hexacetonide

Date Posted: 01 - Sep - 2015

BNF chapter: Musculoskeletal system

Expand/Collapse

Osteoarthritis

NICE CG177 - Osteoarthritis: Care and management in adults

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Amber 2

Pending

Sulfasalazine

Date Posted: 01 - Oct - 2014

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid arthritis

Amber 2

Pending

Grey

Amber 2

Pending

Grey

Amber 2

Pending

Pending

Sulfasalazine

Date Posted: 01 - May - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Sero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)

Red

Pending

Pending

Red

Pending

Red

Red

Red

Pending

Tocilizumab

Date Posted: 01 - May - 2013

BNF chapter: Musculoskeletal system

Expand/Collapse

Juvenile Idiopathic Arthritis (JIA) in Adult Patients

Red

Red

Red

Red

Red

Red

Red

Red

Red

Tocilizumab

Date Posted: 01 - Feb - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid arthritis (LSCMMG pathway)

Red

Red

Red

Red

Red

Red

Red

Red

Red

Tocilizumab

Date Posted: 01 - May - 2013

BNF chapter: Musculoskeletal system

Expand/Collapse

Systemic Juvenile Idiopathic Arthritis (NICE TA238)

NICE TA238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

Red

Red

Red

Red

Red

Red

Red

Red

Red

Tofacitinib

Date Posted: 11 - Jan - 2024

BNF chapter: Musculoskeletal system

Expand/Collapse

Active ankylosing spondylitis (NICE TA920)

NICE TA920 - Tofacitinib for treating active ankylosing spondylitis

Breadcrumb

Medicine Recommendations

Severe Eczema, Lichen Planus, Felty’s syndrome (unlicensed)

Severe Psoriatic Arthritis

Off label indications as defined in the LSCMMG Shared Care Guidelines

Acute Gout (as per LSCMMG Guidelines)

Pain

Rheumatic diseases

​​

This colour classification is in agreement with the recommendations contained within the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017

Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)

Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)

Osteoarthritis

Rheumatoid arthritis

Sero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)